Category: Latest News
-
AMC Shares Dip Following Announcement of Debt Restructuring Plan
AMC Entertainment Holdings, Inc. (NYSE:AMC) saw its stock decline by 4% early Tuesday after revealing a new agreement with its creditors to restructure existing debt and bolster its financial stability. By later in the day, the stock had recovered some losses, closing down only 0.5%. The restructuring deal introduces roughly $223 million in fresh capital…
-
Tesla Shares Slide 4% Before Market Open Amid Rising Tensions Between Trump and Musk
Tesla Inc. (NASDAQ:TSLA) saw its stock price fall sharply in premarket trading on Tuesday as the feud between U.S. President Donald Trump and Tesla CEO Elon Musk intensified. Trump accused Musk of benefiting excessively from government subsidies and called for a federal probe into the support Tesla has received. Data from Robinhood (NASDAQ:HOOD) showed Tesla…
-
Dow Jones, S&P, Nasdaq, U.S. Stock Futures Slip as Trump Critiques Powell Ahead of Key Central Bank Gathering
U.S. stock futures edged lower Tuesday after Monday’s robust gains that pushed global markets to fresh intraday peaks. Investors are closely monitoring progress in U.S.-Canada trade talks and the softer U.S. dollar while bracing for important economic data scheduled later this week. As of early Tuesday (07:32 GMT), Dow futures dipped by 30 points (-0.1%),…
-
Dollar Slides to Multi-Year Lows Amid Expectations of Rate Cuts, Trade Optimism, and Fiscal Concerns
The U.S. dollar extended its downward trend on Tuesday, hitting its weakest levels since early 2022 as investors increasingly factor in potential interest rate reductions. At the same time, worries are mounting over the fiscal implications of President Donald Trump’s proposed tax and spending plan. By 04:25 ET (08:25 GMT), the Dollar Index—which tracks the…
-
Gold Prices Rise Sharply Amid Trade Deal Uncertainty Before Trump’s Tariff Deadline
Gold prices surged in Asian trading on Tuesday, fueled by growing investor demand for safe-haven assets amid ongoing uncertainty surrounding U.S. trade talks ahead of the July 9 deadline for tariff reviews set by President Donald Trump. The decline in the U.S. dollar also supported the precious metal’s upward momentum. Spot gold climbed 0.8% to…
-
Oil Prices Slide Back to Pre-Conflict Range Ahead of OPEC+ Meeting
On Tuesday, oil prices fell to their lowest levels in three weeks, retreating to figures last seen before the recent escalation of tensions between Israel and Iran. The decline reflects reduced concerns about supply interruptions and expectations of a production increase from OPEC and its allied nations. September Brent crude futures slipped 0.3% to $66.57…
-
U.S. Stocks Add To Last Week’s Strong Gains Amid Trade Deal Optimism
Stocks moved mostly higher over the course of the trading session on Monday, adding to the strong gains posted last week. With the continued upward move, the Nasdaq and the S&P 500 once again set new record closing highs. The major averages reached new highs late in the session before giving back some ground going…
-
U.S. Stocks Reach Highs as Technology and Financials Lead Gains
U.S. stocks rise significantly midday, with the S&P 500 and Nasdaq hitting record highs, fueled by optimism on trade negotiations and expectations of interest rate cuts. Key sectors include technology and financials, enhanced by positive developments like changes in corporate regulations and new revenue projections from major firms. Market sentiment will hinge on upcoming economic…
-
Chemed Stock Drops as Florida Medicare Headwinds Cloud Outlook
Shares of Chemed Corporation (NYSE:CHE) tumbled 14% following a company update that revealed disappointing Medicare admission trends in Florida, triggering concerns over revenue constraints at its hospice unit, VITAS. Chemed now estimates that its VITAS subsidiary could face a Medicare Cap revenue limitation ranging between $18 million and $25 million for the U.S. government’s 2025…
-
Arcturus Therapeutics Stock Rises After Promising Mid-Stage Data for OTC Deficiency Treatment
Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) edged up 2% after the company shared encouraging interim results from two Phase 2 trials evaluating its investigational mRNA therapy, ARCT-810, for patients with ornithine transcarbamylase (OTC) deficiency. The biotech firm reported that ARCT-810 produced significant biological responses across both clinical studies. Notably, the therapy led to consistent…